80048983 - Updates in Lung Cancer, Immunotherapy, and Immune-related Toxicity: The Fourth Year

Monday, May 6, 2019, 7:00 AM - Tuesday, May 7, 2019, 4:00 PM, Owens Auditorium, Baltimore, MD


Lung cancer is the leading cause of cancer death in the United States, with an estimated 220,000 new diagnoses of lung cancer in 2018 resulting in more than 150,000 deaths, making lung cancer more deadly than breast, prostate and colon cancer combined. Although the number of new cases of lung cancer is declining, the death rate from lung cancer continues to be staggering. Among new diagnoses in the United States, approximately 40% occur in current smokers, 40% in former smokers, and 20% in patients who have never smoked. Difficulties faced in the treatment of lung cancer are compounded by the frequent late stage of diagnosis in combination with associated environmental and genetic factors.

Recent advances in lung cancer research have provided improved understanding and stratification of different types of non-small-cell lung cancer. This has led to a further research which has and continues to identify targetable molecular and genetic mutations as well as biomarkers of immunotherapeutics. As our knowledge improves, the previous practice to treat all non-small-cell lung cancer with cytotoxic chemotherapeutic agents has undergone immense change. We are now entering an era of personalized therapy in which lung cancer is characterized by specific potentially targetable genetic alterations and biomarkers to immunotherapy. Recognizing these targets, developing and testing targeted chemotherapeutics, evaluating mechanisms of tumor resistance and suitability for immunotherapy require a multi-disciplinary approach and collaborative efforts.

As our experience with and use of immunotherapeutics in lung cancer grows so to does the recognition of the differing types of immunotherapy related adverse events (irAE). These irAEs are of great consequence in that they can be associated with significant morbidity and even mortality but often force the physician to hold highly effect therapy. In addition to Day One of the conference which will highlight the recent advances in lung cancer screening, diagnostics and treatment, Day Two will be presented as a master class focusing on organ specific immunotherapy related adverse events and their management in order to aid the practicing clinician in their management of immunotherapy and irAE.

WHO SHOULD ATTEND
This activity is intended for physicians with specialties in pulmonary and critical care, internal medicine, family medicine, thoracic surgery, medical oncology, radiation oncology, pathology, nurses, nurse practitioners, physician assistants, respiratory therapists, physician trainees, students, residents, and fellows.

FEES
LIVE ACTIVITY
Physicians:...............................................$495.00
Physicians - Day 1 only:........................ $295.00
Physicians - Day 2 only:........................ $295.00

Residents/Fellows/Nurses/NP's/PA's/Pharmacists/AHP:...................................$150.00
Residents/Fellows/Nurses/NP's/PA's/Pharmacists/AHP - Day 1 only:............. $100.00
Residents/Fellows/Nurses/NP's/PA's/Pharmacists/AHP - Day 2 only:..............$100.00
*with verification of status

LATE FEE AND REFUND POLICY
A $50 late fee applies to registrations received after 5:00 p.m. ET on April 30, 2019. A handling fee of $50 will be deducted for cancellation. An additional fee may apply for cancellation of other events, including workshops and social activities. Refund requests must be received by fax or mail by April 30, 2019. No refunds will be made thereafter. Transfer of registration to another Johns Hopkins activity in lieu of cancellation is not possible.

1. Describe the appropriate selection of diagnostic modalities in the work-up of a patient with suspected lung cancer.
2. Identify and describe updates and advances in chemotherapy treatment for patients with advanced lung cancer.
3. Discuss new advances in immunotherapy in the treatment of lung cancer.
4. Identify and describe organ specific immunotherapy related adverse events as well as their management.
5. Evaluate patients with malignant airway obstruction, mediastinal/hilar lymph adenopathy and peripheral lung lesions.
6. Evaluate patients with newly diagnosed lung nodules.
7. Discuss novel non-invasive detection of lung cancer.
8. Discuss the side effects associated with new chemotherapeutic agents and their management.

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MAINTENANCE OF CERTIFICATION
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14 Medical Knowledge only MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

OTHER CREDITS
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

PAs may claim a maximum of 14 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

The Johns Hopkins University has approved this activity for 14 contact hours for non-physicians.

Residence Inn Baltimore at The Johns Hopkins Medical Campus
800 N. Wolfe St.
Baltimore, MD 21205
Phone: (443) 524-8400
Room Rate: $149

Make Reservation Online
Reservation Cut-Off Date: 4/22/19. After Cut-Off, please contact Terry McNair at [email protected].